fashion -WSS

fashion

author：comprehensive 2025-09-06 02:13:01 - browse：4187

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： 'Null' research findings aren't empty of meaning. Let's publish them

knowledge

WSS

Study: AI not yet building 'n

Elevance, private equity launch primary care company

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

H5N1 communication has been strictly for the birds

CDC wastewater surveillance dashboard to track bird flu hotspots

Telehealth startups turn to complex chronic diseases

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Hollywood unions extend contract negotiations for actors

A controversial new treatment promises to make little people taller

State Dept. review finds Biden bears some blame for Afghanistan failures

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

At least 13 dead in Texas as scorching temps continue

Late stage cancers on the rise after pandemic delayed screenings

How one medical school became remarkably diverse

CDC wastewater surveillance dashboard to track bird flu hotspots

Walensky prepares to leave CDC — and Congress — behind

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

focus

Flint parents haunted by uncertainty, fears of lead poisoning

Flint parents haunted by uncertainty, fears of lead poisoning

FDA approves Sage Therapeutics’ rapid

The a glaring gap in research on serious mental illness and primary care

A controversial new treatment promises to make little people taller

A controversial new treatment promises to make little people taller

knowledge

explore

focus

explore